Your session is about to expire
← Back to Search
Other
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Verified Trial
Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 48
Summary
This trial is testing a new medication called LY3437943 to help people who are obese or overweight lose weight. The study will last over a year and involve multiple visits. The medication works by affecting the body's metabolism and appetite to promote weight loss.
Eligible Conditions
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 48
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 48
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Mean Change From Baseline in BMI
Mean Change From Baseline in Body Weight
Mean Change From Baseline in Waist Circumference
+4 moreSide effects data
From 2022 Phase 2 trial • 281 Patients • NCT0486778520%
Decreased appetite
20%
Nausea
15%
Diarrhoea
11%
Constipation
11%
Vomiting
11%
Upper respiratory tract infection
11%
Urinary tract infection
7%
Fatigue
7%
Dyspepsia
4%
Anaemia
4%
Covid-19
4%
Lipase increased
4%
Dizziness
4%
Weight decreased
2%
Cellulitis
2%
Diabetic ketoacidosis
2%
Abdominal pain
2%
Eructation
2%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3437943 (2 mg)
8 mg LY3437943 (2 mg)
Placebo
1.5 Milligram (mg) Dulaglutide
0.5 mg LY3437943
4 mg LY3437943 (2 mg)
4 mg LY3437943 (4 mg)
8 mg LY3437943 (4 mg)
Trial Design
7Treatment groups
Experimental Treatment
Placebo Group
Group I: 8 mg LY3437943 (4 mg)Experimental Treatment1 Intervention
Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
Group II: 8 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
Group III: 4 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
Group IV: 4 mg LY3437943Experimental Treatment1 Intervention
Participants received 4 mg LY3437943 administered as SC injection QW.
Group V: 12 mg LY3437943 (2 mg)Experimental Treatment1 Intervention
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.
Group VI: 1 milligram (mg) LY3437943Experimental Treatment1 Intervention
Participants received 1 mg LY3437943 administered as SC injection QW.
Group VII: PlaceboPlacebo Group1 Intervention
Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3437943
2022
Completed Phase 2
~1090
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,679 Previous Clinical Trials
3,465,415 Total Patients Enrolled
69 Trials studying Obesity
46,223 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,389 Previous Clinical Trials
427,830 Total Patients Enrolled
51 Trials studying Obesity
24,996 Patients Enrolled for Obesity